Lttl Review – We Get Paid $375 If You Start Semaglutide Here

Read Our Conflict of Interest First

We are telling you this before anything else because you cannot properly weigh the rest of this page without it. A financial incentive of that size, on a medical decision, is exactly the circumstance in which a reader should discount what they are being told — including by us.

What follows is built almost entirely from the FDA’s own published material rather than from the company’s claims or ours, precisely so that you can check it against a source with no stake in your decision. All details were checked on 8 August 2026.

This article is informational only and is not medical advice. Decisions about GLP-1 medication belong with a clinician who knows your history.

These Are Compounded, and Lttl Says So

The most important product fact, and the company states it clearly on its own site.

We want to credit that properly, because it is unusually direct. Many sellers in this category bury the distinction or imply equivalence with Ozempic and Zepbound. Lttl states it plainly, and that is the disclosure the FDA wants made.

One phrase deserves unpacking, because it does a lot of quiet work across this whole industry: “FDA-registered facilities.” Registration means a facility has told the FDA it exists and is subject to inspection. It is not approval of anything made there, and it is not a quality finding — as the rest of Lttl’s own sentence makes clear.

Prices are $129 a month for semaglutide and $199 for tirzepatide, with microdose plans from $109 and longevity plans from $79, pricing held flat across dose escalation, no contracts, and FSA/HSA eligibility.

The FDA Standard That Actually Governs This

This is the single most important paragraph on this page, and it is the FDA’s language rather than ours.

Read what that test is about. It is a clinical question about your individual circumstances — whether an approved product can meet your need. It is not a price comparison.

“The approved version is more expensive” is not the same as “my medical need cannot be met by the approved version” — and the overwhelming reason people buy compounded GLP-1s is price.

That is not a criticism of anyone’s finances. These drugs are extremely expensive and coverage is patchy, and we understand entirely why a $129 monthly subscription is attractive against branded pricing. But you should go in understanding that the FDA’s framework for when compounding is appropriate is a clinical one, and that a mass-market subscription is not obviously what that framework contemplates.

The FDA Publishes a Checklist. Here Is Lttl Against It.

The FDA publishes a list of “telehealth red flags for consumers” for precisely this category. That is a better assessment framework than anything we could invent, so we have applied it directly and reported honestly where we could not check.

Lttl clears the two flags we could check, and clears the first one well. That is a genuine result and we report it as such.

The screening deserves one caveat. The intake is described as a free two-minute assessment quiz, after which licensed clinicians review and prescribe. A licensed clinician is genuinely involved, which is what the FDA flag asks about. But two minutes of self-reported answers is a thin foundation for a drug with real contraindications — be scrupulously honest in that questionnaire, because it is substantially all the clinician has.

The Adverse Event Numbers, and the Underreporting Caveat

The FDA’s own caveat is the important part, and it points in the direction people usually assume it does not: federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to the FDA, so the agency states it is “likely that adverse events from compounded versions of these drugs are underreported.”

So those are floors, not totals. A reporting system with a structural gap produces numbers that understate rather than overstate.

In fairness, the FDA also states that many of the adverse events reported for compounded products appear consistent with those related to the FDA-approved versions — meaning much of this is the known side-effect profile of the drug class rather than something unique to compounding. And it notes it is not always possible to determine whether an event resulted from the drug. Both belong in an honest account.

Dosing Errors Are the Compounded-Specific Danger

This is the risk that genuinely distinguishes compounded from branded, and it is the one to understand before ordering.

Note that both halves of that sentence matter. It is not only patients getting it wrong — the FDA records professionals miscalculating too.

The FDA separately reports adverse events that may relate to patients being prescribed doses beyond what is in the FDA-approved label — meaning more product in a single dose, doses taken more frequently, or titration escalated more quickly. Some of those events were serious and some patients sought medical attention, with nausea, vomiting, diarrhoea, abdominal pain and constipation reported.

The mechanism behind the measurement errors is worth stating, because it is structural rather than careless. An approved product is generally supplied as a pen that doses by dialling a number. Compounded product is frequently supplied as a vial from which you draw up a volume with a syringe — which converts a dose into an arithmetic and manual-dexterity task performed by the patient, at home, often for the first time.

That is why hospitalisations from dosing errors show up here and not with pens. The FDA’s own advice is to talk to your provider or compounder about how to measure and administer the intended dose — which is worth doing before the first injection, not after a mistake.

Ask Whether It Is a Salt Form

A specific, checkable question that most buyers do not know to ask.

That is unusually blunt regulatory language, and it converts into a simple question you can ask before ordering: is this semaglutide base, or a salt form?

We could not establish which form Lttl’s pharmacy partners use, and we are not suggesting it is a salt. We are saying it is a question with a right answer that you are entitled to get in writing.

Pharmacies That Do Not Exist

The FDA reports being aware of fraudulent compounded semaglutide and tirzepatide marketed in the US containing false information on the product label.

• In some cases the compounding pharmacies named on the labels do not exist.
• In others, labels bear the name of a real licensed pharmacy that did not compound the product.
• The FDA notes one adverse event report from a product labelled as compounded tirzepatide from a pharmacy that did not make it, with redness, injection site swelling, pain and a red lump.

This is not an allegation about Lttl — it is a category-wide problem the FDA has documented, and it is why the agency’s red-flag list includes checking the pharmacy name on your label.

The practical step: when it arrives, look up the pharmacy named on the label independently and confirm it exists and is licensed in its state. That takes two minutes and is the single check the FDA’s own guidance points at.

Related: the FDA states retatrutide and cagrilintide cannot be used in compounding under federal law, and has warned telehealth companies for marketing unapproved drugs such as retatrutide. We saw no indication Lttl offers either, which is a point in its favour — and if any provider offers you retatrutide, that alone tells you what you need to know.

If It Arrives Warm, Do Not Use It

This is the most immediately actionable thing on this page for anyone already subscribed. A mail-order cold chain has more failure points than a pharmacy counter, and the instruction is not “use your judgement” — it is not to use it.

Be at home for delivery if you can, open it immediately, and photograph the packaging and ice pack condition on arrival — because if you do need to argue for a replacement, that photograph is your evidence.

The Longevity Peptides Are a Separate Question

Alongside GLP-1s, Lttl sells sermorelin, NAD+, MIC B12, L-carnitine, glutathione and methylene blue as “longevity” products from $79 a month. These deserve a lower level of confidence than the GLP-1s, which at least have an approved counterpart with a large evidence base.

On sermorelin: a PubMed search for sermorelin randomised controlled trials returned only 16 results — a thin literature for something sold as a longevity treatment. The trial we read concerned a related growth-hormone-releasing compound in 32 subjects, and found it raised circulating growth hormone and IGF-1 against placebo.

On methylene blue, one specific safety point. A PubMed search for methylene blue and serotonin syndrome returns 64 papers. We did not read them and are not characterising the mechanism — but a literature that size on one specific drug interaction is itself a signal. If you take an SSRI, SNRI or any serotonergic medication — which is a very large number of people — raise this with a prescriber before buying methylene blue from anyone.

Our position: the GLP-1 offering has a real evidence base behind the molecule even where the compounded form does not. The longevity line does not have that. Treat them as different purchases with different levels of support.

What Lttl Does Better Than the Category

This review has been heavy on risk, so here is what genuinely counts on the other side — particularly since our commission gives us every incentive to overstate it, and we have tried not to.

• The compounding disclosure is explicit and prominent. Stating outright that products are not FDA-approved and not evaluated for safety, efficacy or quality is what the FDA asks for and what much of this industry avoids. It is the single best thing about them.
• Licensed clinicians with stated discretion to decline. The disclaimer that providers “retain full discretion to prescribe or decline” matters — a service that cannot say no is not a clinical service.
• No apparent retatrutide or cagrilintide, which cannot lawfully be compounded and which the FDA has warned telehealth companies over.
• Flat pricing across dose escalation. This is quietly important: if the price rises with dose, a patient has a financial reason to under-titrate, which is a bad incentive to put on a drug that works by titration.
• No contracts, cancel anytime, FSA/HSA eligible, as stated.

What We Could Not Verify

• Whether a clinician is available after you receive medication — an explicit FDA red flag, and the one we most wanted to check.
• Which pharmacies actually compound the product, or whether they use semaglutide base or a salt form.
• Refund and cancellation terms. The site references a returns and refunds page; we could not locate it at the URLs we tried, so “cancel anytime’ is unverified in its detail.
• Any regulatory action, complaint record or litigation. We had no means of checking, so treat that as unexamined rather than clean.

Given the commission we stand to earn, we would rather list these plainly than let their absence read as endorsement.

What to Do Before and After You Order

Before:

• Ask your own doctor first. The FDA’s test is whether an approved drug can meet your need — that is a clinical judgement, and it is worth getting from someone who is not selling you the alternative.
• Check coverage for approved products properly, including manufacturer savings programmes, before concluding compounded is the only affordable route.
• Ask whether it is semaglutide base or a salt form, and get it in writing.
• Ask which pharmacy compounds it, and whether a clinician is reachable afterwards.
• Be completely honest in the intake questionnaire. It is most of what the prescriber has.

On arrival:

• Do not use it if it is warm or the ice packs have failed. Photograph it.
• Look up the pharmacy named on the label and confirm it exists and is licensed.
• Check the label for spelling errors and a plausible address — both are on the FDA’s red flag list.
• Have someone walk you through measuring the first dose. Dosing errors have put people in hospital, and a vial and syringe is not a pen.
• Do not escalate the dose faster than the label supports, and report side effects rather than pushing through them.

Pros and Cons

Limitations of This Review

A note on method. Our general web search capability was exhausted before this review, so it was built from the FDA’s own published drug safety pages, direct PubMed queries, and the company’s own site. That makes the regulatory content unusually well sourced — the adverse event figures, dosing warnings, salt form position and red-flag checklist are quoted from the FDA’s own current page, not from press coverage.

But it leaves gaps we would normally close, and they matter more here than anywhere else. We did not examine complaint records, litigation, state pharmacy board actions, independent testing of any compounded product, or customer reports of the service in practice. Treat all of those as unexamined rather than clean.

We have not used Lttl, ordered from it, or spoken to its clinicians. Everything about its model, pricing, clinician involvement and cancellation terms is the company’s own statement, unverified by us. Prices change.

On the FDA material: it is current as we read it but this is a fast-moving area — compounding rules, shortage status and enforcement have changed repeatedly, and you should read the FDA’s page yourself rather than relying on our summary. The peptide comments rest on search counts and one abstract, not a literature review; we explicitly did not read the methylene blue papers and report only that they exist in number.

Nothing here is medical advice, and we are not competent to tell you whether a GLP-1 is appropriate for you. That is a conversation with a clinician who knows your history — ideally one who does not earn anything from your answer, which is more than we can say for ourselves on this page.

Frequently Asked Questions

Verdict

We disclosed the $375 first and we will end with it too, because it is the largest commission on this site by a wide margin and it attaches to a prescription decision. Discount us accordingly.

Lttl deserves real credit for one thing above all. It states outright that its compounded medications are “not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality.” Much of this industry implies the opposite. It also clears both FDA telehealth red flags we could check, uses licensed clinicians with stated discretion to decline, appears not to touch retatrutide, and holds price flat across dose escalation — which removes a financial reason to under-titrate.

But honest labelling does not change what is in the vial, and the FDA’s record on this category is substantial. 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide as of 31 May 2026 — figures the agency says are likely underreported, because pharmacies that are not outsourcing facilities are not required to report at all. Multiple adverse events, some requiring hospitalisation, from dosing errors — by patients and, the FDA notes, by professionals miscalculating. Salt forms the agency says it knows no lawful basis for. Fraudulent products naming pharmacies that do not exist. Deliveries arriving warm.

And the standard that governs all of it is not about price. The FDA’s position is that compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug.” The reason nearly everyone buys compounded GLP-1s is that they are cheaper. Those are different tests, and we would rather say so than let a $375 commission talk us out of it.

If you go ahead anyway — and we understand exactly why people do, because these drugs are expensive and coverage is patchy — ask whether it is base or a salt form, look up the pharmacy on the label, refuse it if it arrives warm, have someone teach you to measure the first dose, and do not escalate faster than the label supports.

And ask a doctor who is not paid by the outcome. Including us.